Voya Financial, Inc. (VOYA) Stock Price & How to Invest

Voya Financial, Inc. (NYSE: VOYA) is a New York headquartered retirement, employee benefits and investment management company with roughly 11,000 employees (about 71% US-based and 29% in its services center in India) and more than ~18 million individual customer relationships. It reports in three segments. Retirement is the largest: it administers defined contribution plans for approximately 45,000 US employers, crossed ~10 million participant accounts during the second quarter of 2026, and held ~$863 billion of total client assets as of June 30, 2026, up ~14% year over year after the completed integration of the OneAmerica full-service retirement business. Voya Investment Management ran ~$377 billion of assets under management plus ~$63 billion of assets under advisory, with Allianz holding a ~24% stake in the VIM Holdings entity. Employee Benefits sells group life, disability, voluntary products and medical stop-loss, with ~$3.59 billion of annualized in-force premiums and fees.

The investment picture turns almost entirely on the stop-loss book, because that is where the earnings volatility lives. Trailing twelve month revenue was ~$8.17 billion and net income available to common shareholders was ~$567 million, but second-quarter 2026 after-tax adjusted operating earnings fell to ~$140 million, or ~$1.51 per diluted share, from ~$240 million and ~$2.46 a year earlier. Employee Benefits pre-tax adjusted operating earnings dropped to ~$22 million from ~$69 million as the quarterly stop-loss loss ratio ran at ~85.4% against ~80.3% in the prior-year quarter. The longer arc looks better: the trailing twelve month aggregate loss ratio improved to ~74.3% from ~79.0%, and segment adjusted operating earnings on that basis rose to ~$122 million from ~$36 million. The central question is whether repricing has actually fixed the block, or whether adverse prior-year claims development keeps arriving each January renewal season.

Medical stop-loss claims are reported and reserved on a policy-year basis with most policies renewing in January, so a bad trend surfaces in concentrated bursts rather than gradually, and the ~$91 million of adverse prior-year development booked in the first half of 2026 shows the reserve estimate can still move against the company. Roughly half of quarterly operating earnings come from fee-based revenue tied to market levels, meaning a sustained equity drawdown reduces both Retirement and Investment Management earnings at the same time. Alternative investment income has been a recurring drag, costing ~$15 million pre-tax in the second quarter of 2026 alone. The TOMS Capital referendum has no binding legal effect and the board is under no obligation to act on it, so any part of the current share price that reflects sale expectations rests on an outcome nobody has agreed to. Separately, Voya is a defendant in Ravarino, et al. v. Voya Financial, Inc. (D. Conn., No. 3:21-cv-01658, filed December 14, 2021), a putative ERISA class action over the administration of its own 401(k) plan in which plaintiffs filed an amended complaint on December 10, 2025; this is a fiduciary-duty case, not a securities-fraud action, and the company disclosed an accrual of up to approximately $25 million for certain matters.

12 analysts publish price targets on VOYA, averaging $108.08 against a $100.56 price as of August 2026, or +7.5%. The published targets run from $90.00 to $125.00, a moderate spread, and the ratings split 8 buy, 3 hold, 1 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full VOYA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Voya Financial, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The stop-loss repricing cycle. Voya has spent three renewal seasons raising stop-loss prices and walking away from business it does not want, which is why annualized in-force premiums and fees of ~$3.59 billion were roughly flat year over year while margins moved. The most optimistic published target, $125.00, assumes this works close to its best case.

The case against. Medical stop-loss claims are reported and reserved on a policy-year basis with most policies renewing in January, so a bad trend surfaces in concentrated bursts rather than gradually, and the ~$91 million of adverse prior-year development booked in the first half of 2026 shows the reserve estimate can still move against the company. The most pessimistic target, $90.00, is roughly what VOYA is worth if this bites instead.

Read the full bull and bear case on VOYA, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Voya Financial, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$8.17B
• Net income to common (TTM): ~$567M
• Q2 2026 adjusted operating EPS: ~$1.51 (vs ~$2.46 a year earlier)
• Market cap: ~$9.1B at ~$100 per share
• P/E (trailing / forward): ~16.9x / ~9.5x
• Dividend: ~$1.88 per share annualized, ~1.9% yield

The gap between a trailing multiple near ~16.9x and a forward multiple near ~9.5x is the whole debate in one number: the market is pricing a recovery in Employee Benefits earnings that has not yet appeared in reported results. Shares traded around ~$100 in late August 2026 against a 52-week range of roughly ~$64.50 to ~$103.85, so the stock has already re-rated substantially from its lows since the activist campaign became public in April. Shareholders' equity was ~$4.69 billion at June 30, 2026, and the company held ~$200 million of excess capital at the holding company after repaying maturing debt, down from ~$650 million three months earlier.

Other names that sit close to VOYA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get VOYA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so VOYA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where VOYA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Voya is a scaled retirement and investment management business whose valuation has been set by the medical stop-loss underwriting cycle, and since spring 2026 by a public campaign pressing the board to review strategic alternatives.

Whether VOYA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VOYA a buy or a sell?, and where the stock could go from here in the VOYA stock forecast.

For income investors, whether VOYA pays a dividend and how the payout looks is covered in does VOYA pay a dividend? And to weigh VOYA against a peer, read the full side-by-side comparisons: VOYA vs PFG and VOYA vs SLF.